Abstract:Background: Ciprofloxacin is usually used in the treatment of lower respiratory tract infections (LRTIs). Recent studies abroad have shown ciprofloxacin is inadequately dosed and might lead to worse outcomes. The aim of this study was to perform pharmacokinetic and pharmacodynamic analyses of ciprofloxacin in elderly Chinese patients with severe LRTIs caused by Gramnegative bacteria. Methods: From September 2012 to June 2014, as many as 33 patients were empirically administered beta-lactam and ciprofloxacin combination therapy. Patients were in fused with 200 or 400 mg of ciprofloxacin every 12 h, which was determined empirically by the attending physician based on the severity of the LRTI and the patient's renal condition. Ciprofloxacin serum concentrations were determined by high-performance liquid chromatography. Bacterial culture was performed from sputum samples and/or endotracheal aspirates, and the minimum inhibitory concentrations (MICs) of ciprofloxacin were determined. The ratios of the area under the serum concentration-time curve to the MIC (AUC/MIC) and of the maximum serum concentration of the drug to the MIC (C-max/MIC) were calculated. The baseline data and pharmacokinetic parameters were compared between clinical success group and clinical failure group, bacteriologic success group and bacteriologic failure group. Results: Among the 33 patients enrolled in the study, 17 were infected with Pseudomonas aeruginosa, 14 were infected with Acinetobacter baumannii, and two were infected with Klebsiella pneumoniae. The mean age of the patients was 76.9 +/- 6.7 years. Thirty-one patients (93.4%) did not reach the target AUC/MIC value of >125, and 29 patients (87.9%) did not reach the target C-max/MIC value of >8. The AUC/MIC and C-max/MIC ratios in the clinical success group were significantly higher than those in the clinical failure group (61.1 [31.7-214.9] vs. 10.4 [3.8-66.1], Z= -4.157; 9.6 [4.2-17.8] vs. 1.3 [0.4-4.7], Z= -4.018; both P< 0.001). The AUC/MIC and C-max/MIC ratios in the patients for whom the pathogens were eradicated were significantly higher than those in the patients without the pathogens eradicated (75.3 [31.7-214.9] vs. 10.5 [3.8-66.1], Z. 3.938; 11.4 [4.2-17.8] vs. 1.4 [0.4-5.4], Z.-3.793; P < 0.001 for both). Receiver operating characteristic curve analysis showed that the AUC/MIC and C-max/MIC values were closely associated with clinical and bacteriologic efficacies (P < 0.001 in both). Conclusions: Ciprofloxacin is inadequately dosed against Gram-negative bacteria, especially for those with relatively high MIC values. Consequently, the target values, AUC/MIC > 125 and C-max/MIC > 8, cannot be reached.

Comparative analysis on effective of cefoperazone and imipenem in treatment of G- bacteria infection in elderly patients

A randomized controlled study on cefpirome versus ceftazidime in the treatment of bacterial infections

Pharmacoeconomics on Treatment of Gram-Negative Bacteria Infections with Cefoperazone-Sulbactam, Imipenem-Cilastatin, and Piperacillin-Tazobactam

Curative Effect Analysis of Cefoxitin Sodium in the Treatment of Senile Bacterial Lower Respiratory Tract Infection

Efficacy of cefepime on the treatment of senile with lower respiratory infections

Comparison of clinical efficacy of imipenem and cefoperazone/sulbactam in treatment of hospital-acquired pneumonia in patients with hematologic malignancies

Effect of Pulmonary Infection Score on Intervention to Selection of Antibiotics and Prognosis of the Elderly Patients with Severe Pneumonia

Comparison of omadacycline and meropenem plus linezolid in treatment of pulmonary infection: A real-world cohort study

Clinical Evaluation of Effect and Safety of Cefepime on 383 Patients with Moderate or Severe Infection

Comparison of antibacterial activities of cefepime and 4 others antibiotics against gram-negative Bacilli isolated

Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients

Pharmacokinetic study of cefazolin and ceftazidime in the elderly

Efficacy of teicoplanin in treatment of Gram-positive coccal lower respiratory tract infection among elderly patients.

Clinical Effect of Antibiotic Therapy in The Treatment of Severe Pneumonia in Elderly Patients

Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria.

Clinical evaluation on the empirical treatment of community acquired pneumonia

Analysis of the Medication of Elderly Patients with Community-acquired Pneumonia in Our Hospital from 2010 to 2012

Comparison of antibacterial activities of different concentrations of the cefoperazone-sulbactam combination disc upon commonly found gram negative bacilli

A Randomized Controlled Study of Cefoperazone-Tazobactam Versus Cefoperazone-Sulbactam in the Treatment of Bacterial Infections

Comparative analysis of pathogens in lower respiratory tract infections between elderly patients and young patients

A Comparison of in Vitro Activity Between Cefprozil and Other Antimicrobial Agents Against Pathogens in Community-Acquired Respiratory Tract Infections